Michael DiMaio
Associate
Michael DiMaio joined the corporate department as an associate in 2016, working primarily in the health care group. Michael advises health care providers, pharmaceutical and medical device manufacturers, and other health care organizations regarding a broad range of transactional, regulatory, compliance, and financing issues.
During law school, Michael worked at the Massachusetts Health Policy Commission in the Registration of Provider Organizations group and at Greater Boston Legal Services in the Elder, Health, and Disability Unit.
Experience
- Advised a durable medical equipment manufacturer and supplier regarding regulatory due diligence concerns in connection with a strategic acquisition of another supplier.
- Advised a private equity sponsor regarding regulatory matters in connection with acquisitions involving laboratory equipment manufacturers.
- Advised private equity sponsors regarding assessment of revenue cycle management companies.
- Advised a contract research organization regarding regulatory due diligence concerns in connection with a potential strategic acquisition of another contract research organization.
- Advised a private equity sponsor regarding its acquisition of a care coordination company.
- Counseled an academic medical center on a potential affiliation with a large health system and provided advice with respect to diligence matters.
- Assisted tax-exempt borrowers obtain tax-exempt financings.
Publications
- Co-author, “Guidance Regarding Interaction Between GDPR and EU Clinical Trials Regulation Leaves Several Questions Unanswered,” Bloomberg Law (February 14, 2019)
- Co-author, “Insights On Right To Try Act And 'Expanded Access' Concerns,” Law360 (December 18, 2018)
- Co-author, “INSIGHT: Kickbacks or Common Sense Business? Hurdles for Value-Based Care,” Bloomberg Law’s Health Law and Business (December 10, 2018)
- Co-author, “Delaware appraisal decisions,” International Law Office Corporate Finance/M&A Newsletter (December 5, 2018)
- Co-author, “Use of 'ticking fee' in Novartis-AveXis transactions,” International Law Office Corporate Finance/M&A Newsletter (November 14, 2018)
- Co-author, “Will Consent Be Disfavored as Basis for Processing Personal Data in Clinical Research Under EU Data Protection Law?” Bloomberg Law’s Medical Law & Research Policy Report (June 15, 2018)
- Co-author, “What To Know About HHS Revised 'Common Rule',” Law360 (Feb. 13, 2017)
Presentations
- Presenter, “Implications of GDPR for Collection and Sharing of Clinical Trial Data,” 6th Annual Clinical Data Disclosure and Transparency Conference (January 29, 2019)